ALTANA Pharma investment runs into triple-digit millions

Extension of the Singen production facility

05-Jul-2004

ALTANA Pharma AG remains on course for further international growth. A new building for producing active substances for use in pharmaceutical preparations has just been opened.

An official ceremony to mark the extension of the Singen production facility was held last week in the presence of Erwin Teufel MdL, Prime Minister of the State of Baden-Wuerttemberg, as well as numerous other representatives from politics, the media and industry.

ALTANA Pharma AG, an international pharmaceuticals company, has made substantial investments in the region, which is also home to its headquarters: in the past 3 years over 75 million euros have gone into the production plant in Singen alone whilst in Constance, the main research hub, 100 million euros have been spent on new buildings. This has resulted in the creation of over 700 new jobs for highly qualified personnel. Research and development costs for new and highly active preparations have totaled some one billion euros since 1999.

State Prime Minister Teufel praised the company's commitment. "ALTANA Pharma is a multifaceted partner and provider of impetus to the region. In the past two years, ALTANA has created over 470 jobs. It has also cultivated close contacts with universities, leading the necessary process of structural change towards research and know-how intensive industries and services.

Its Innovation Fund to promote new start-ups and its Cultural Forum are further examples of ALTANA's huge commitment in and beyond its main area of business, and bear witness to a keen sense of responsibility for the future of the entire region.".

Dr. Hans-Joachim Lohrisch, Chairman of the Management Board of ALTANA Pharma AG, stressed the need for innovation in his speech. "As a research-oriented pharmaceuticals company we are reliant on innovation and must have a dependable framework in which to operate. Our business locations in Germany will only benefit by our growth if we see an improvement in the underlying conditions for innovation."

The new W 32 building in Singen will house the facilities for producing the active substances Pantoprazole and Roflumilast (Daxas®). Used to treat acid-induced gastrointestinal diseases, Pantoprazole generated market sales of 2.35 billion euros in 2003 and is currently the most successful drug ever to emerge from a German research laboratory.

https://www.bionity.com/en/news/38353/altana-pharma-investment-runs-into-triple-digit-millions.html